We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Within the Next 10 Years it is Anticipated that Metabolomics will Become a Standard Tool in the Pharma Industry

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Research and Markets has announced the addition of "The Future of Metabolomics: Building Competitive Advantage in Drug Discovery, Clinical Development and Diagnostics" to their offering.

Metabolomics is a dynamic and emerging field, joining genomics, transcriptomics and proteomics in enabling an integrative systems biology approach to drug discovery and development.

Although metabolomics is still at an early evolutionary stage it is forecast that over the next decade the biopharma industry will apply this technology more widely in drug development and data obtained will be used in drug filing and optimizing the lifecycle management of marketed drugs.

'The Future of Metabolomics' provides detailed insight into the effective use of metabolomics throughout drug discovery, preclinical development and clinical trials.

The report also highlights the use of metabolomics in maximizing and sustaining revenues post-marketing and in the development of clinical diagnostics.

Use up-to-date case studies to understand current and future directions in the application of metabolomics to drug discovery and development, explore potential cost savings, and recognize lucrative partnering opportunities in this fast moving field.

Key Features:

- An update on how regulatory authorities in the US and Europe are preparing for the use of metabolomics and biomarker data in drug submissions.

- In-depth case studies on how leading metabolomics innovators and pharmaceutical companies are applying metabolomics at all stages of the drug and diagnostic development process.

- Analysis of the platform technology, service and bioinformatics companies at the forefront of the metabolomics market.

- A detailed breakdown of the potential of metabolomics to reduce costs, time and attrition rates in drug discovery and clinical development.

Key Findings:

- Future growth of the metabolomics market will be driven by three areas: biomarker discovery services, the application of bioinformatics/chemometrics and the development of technology platforms, leading to a market size of over US $2 billion by 2012.

- Metabolomics can be applied in lifecycle management by identifying new indications for a marketed product, or by developing a test that will optimize dosing and help patients to receive a dose that is both efficacious and safe.

- Metabolomics can be used to uncover new drug targets, prioritize lead compounds, and assess toxicity non-invasively, enabling the development of novel, smarter and safer drugs.

- Within the next 10 years it is anticipated that metabolomics will become a standard tool in the pharma industry as validated metabolomic-based biomarkers begin to emerge and cost-effective screens are established.

Key Topics Covered Include:

- Introduction
- Platform technologies in metabolomics
- Regulatory and standardization issues
- Metabolomics in drug discovery & preclinical development
- Metabolomics in clinical drug development
- The role of metabolomics for marketed drugs
- Metabolomics in diagnostics and health screening
- Market size, alliances, acquisitions and future directions